Rezolute announces positive Phase 3 upLIFT principal efficacy results for ersodetug
The company reported the primary efficacy endpoint was met in the tumor hyperinsulinism study. This milestone marks a step toward potential regulatory approval of ersodetug for refractory hypoglycemia.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed